Clinical Trials Logo

Clinical Trial Summary

The standard treatment of unresectable liver metastasis in gastrointestinal tract cancer is chemotherapy, but considerable portion of the patients progressed and most of the liver is converted to metastatic tumor lesions. Significant quality of life decrement was detected in those patients, especially in patients suffered severe symptoms Several studies reported that whole liver RT (WLRT) can be used effectively to control severe symptoms from unresectable liver metastasis in gastrointestinal tract cancer patients. However, it is well known fact that the liver is a very sensitive to RT. Despite symptom palliation is obtained after 20 to 30 Gy RT but only in small subset of patients get local control. In this aspect, the combined with radiosensitizer with WLRT is considered to enhance RT effect to palliate symptom and control local tumor progression, and increase the quality of life ultimately.

It is reported that hyperthermia is considered as the most valuable radiosensitizer in cancer treatment, theoretically. Based on those studies, we start this prospective study to investigate the effect of combination treatment of WLRT and hyperthermia on quality of life in the patients with unresectable chemoresistant liver metastasis from gastrointestinal tract cancer.


Clinical Trial Description

1.1 gastrointestinal tract cancer liver metastasis Most mortality of the gastrointestinal tract cancer patients is related with distant metastasis, especially liver is the main site. It has been estimated that 25% of colorectal cancer patients have hepatic metastases at diagnosis, and another 50% will have their tumor recurrence in the liver within 5 years.

Selected patients who had oligo (usually 2 to 3) or isolated liver metastases resected curatively and have yielded 5-year survival rates of 50% to 60%, showing that local therapy has the potential to cure. It is only possible in less than 25% of all patients with hepatic metastasis because of medical and/or surgical reasons, furthermore two-thirds of resected patients showed ultimately liver recurrence within 2 years.

The standard treatment of unresectable liver metastasis in gastrointestinal tract cancer is chemotherapy, but considerable portion of the patients progressed and most of the liver is converted to metastatic tumor lesions. Significant quality of life decrement was detected in those patients, especially in patients suffered severe symptoms

1.2 Radiation therapy (RT) for liver metastasis Several studies reported that whole liver RT (WLRT) can be used effectively to control severe symptoms from unresectable liver metastasis in colorectal cancer patients. However, it is well known fact that the liver is a very sensitive to RT. The radiation induced liver disease (RILD), dreadful complication without special treatment method and subset of patients could be dead, can be developed as low as 30 gray (Gy). Despite symptom palliation is obtained after 20 to 30 Gy RT but only in small subset of patients get local control. In this aspect, the combined with radiosensitizer with WLRT is considered to enhance RT effect to palliate symptom and control local tumor progression, and increase the quality of life ultimately.

1.3 Hyperthermia It is reported that hyperthermia is effective in S phase, Low oxygen partial pressure (pO2), low hydrogen ion concentration (pH), and low perfusion site which are known as radio-resistant. Because of these characteristics, it considered as the most valuable radiosensitizer in cancer treatment, theoretically. Furthermore, mild hyperthermia (41 to 41.5 ºC) can promote tumor reoxygenation.

1.4 Purpose of this study Based on those studies, we start this prospective study to investigate the effect of combination treatment of WLRT and hyperthermia on quality of life in the patients with unresectable chemoresistant liver metastasis from gastrointestinal tract cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01963117
Study type Interventional
Source Samsung Medical Center
Contact
Status Terminated
Phase N/A
Start date October 2013
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT04431596 - Military Alerting System for Monitoring Body Temperature During Active Cooling N/A
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT00940654 - The Fever and Antipyretic in Critically Illness Evaluation Study N/A
Active, not recruiting NCT05809453 - Intranasal Cocaine and Temperature Regulation During Exercise Phase 1/Phase 2
Completed NCT04915859 - Semiconductor Heat Extraction Cooling N/A
Completed NCT04613843 - Cold Water Immersion Stirring in Hyperthermic Individuals N/A
Completed NCT03689478 - Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT N/A
Completed NCT02271607 - The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients N/A
Completed NCT04596618 - Impact of ICE on Exercise Performance in the Heat N/A
Withdrawn NCT05710978 - Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain N/A
Completed NCT05586477 - Diphenhydramine and Sweating Phase 4
Completed NCT01576822 - Sauna Detoxification Study: Pilot Feasibility Phase 1
Recruiting NCT05366270 - Peripheral Neuroimmune Mechanisms of Hyperthermia N/A
Recruiting NCT05993910 - Prospective Hyperthermia Database in Cancer Patients (HT Register)
Terminated NCT04104334 - Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC N/A
Not yet recruiting NCT06389604 - Preparing for Heat Waves - Enhancing Human Thermophysiological Resilience N/A
Not yet recruiting NCT05274009 - Protective Cooling Measures to Safeguard Elderly People From Dangerous Summer Heat N/A
Terminated NCT00796900 - Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH) Phase 2/Phase 3
Active, not recruiting NCT02546596 - The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer N/A
Completed NCT05327764 - Work-To-Rest Ratios N/A